HC Wainwright set a $2.00 target price on CytoDyn (OTCMKTS:CYDY) in a research note released on Friday, TipRanks reports. The brokerage currently has a buy rating on the biotechnology company’s stock.
CYDY has been the subject of a number of other reports. Zacks Investment Research cut shares of CytoDyn from a buy rating to a hold rating in a research report on Thursday, March 7th. ValuEngine cut shares of CytoDyn from a buy rating to a hold rating in a research report on Friday, December 21st.
Shares of CytoDyn stock opened at $0.44 on Friday. CytoDyn has a twelve month low of $0.06 and a twelve month high of $0.71. The firm has a market cap of $134.26 million, a P/E ratio of -1.52 and a beta of 0.40.
CytoDyn Inc, a clinical-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus (HIV) infection. Its lead product is PRO 140, a therapeutic anti-viral agent, which is in Phase IIb treatment substitution trial, Phase IIb extension study, Phase IIb/III pivotal trial, and Phase IIb/III investigative trial for HIV; and Phase II trial for graft-versus-host disease.
Further Reading: What is the Quick Ratio?
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.